newsfilter
← Latest News
Business Wire·

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

Agreement is focused on OmnidAb™ single domain technology OmniAb to receive revenue for discovery services as well as potential equity and royalties OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners